$0.91
−12.40%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.04
From 52W high−82.97%
Volume224586.00
Market cap$91.77M
P/E (TTM)—
P/S (TTM)1.6x
Div yield—
Key dataOct 19, 2026
Open
$1.04
From 52W high
−82.97%
Volume
224586.00
Market cap
$91.77M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
18.2
MomentumView details →
1D Return
−12.40%
YTD Return
−80.58%
SummaryUpdated Jun 1, 2026
Cellectis S.A. (NASDAQ:CLLS) is a French clinical-stage biotechnology company founded in 1999 and headquartered in Paris. The company specializes in developing gene-edited immunotherapy treatments for cancer, particularly focusing on allogeneic CAR-T cell therapies that can be manufactured at scale and used across multiple patients. Cellectis has evolved from its early gene-editing platform origins to become a leading developer of "off-the-shelf" cancer immunotherapies, with multiple clinical programs in various stages of development and a significant strategic partnership with pharmaceutical giant AstraZeneca established in 2024.
Similar companies
Latest newsMore news →
SBS Law announced a fraud investigation into Cellectis S.A. and invited CLLS investors to join it.30d agoHolzer & Holzer, LLC announced an investigation into whether Cellectis S.A. complied with federal securities laws after Cellectis said it would exit development of lasme-cel and eti-cel.32d agoCellectis announced that its board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.36d ago